Biotalys financials
Biotalys
69940040QC7E3C0G3X07 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Operating profit (EBIT) | -€20.9M | -€22.5M |
| Finance costs | €502.0K | €557.0K |
| Profit before tax | -€20.5M | -€22.8M |
| Income tax expense | €56.0K | -€38.0K |
| Profit for the year | -€20.5M | -€22.7M |
| — attributable to owners | -€20.5M | -€22.7M |
| Total comprehensive income | -€20.5M | -€22.8M |
| Per share | ||
| Basic EPS | €-65.00 | €-74.00 |
| Free cash flow / share | €-59.02 | €-67.71 |
| Cash flow statement | ||
| Cash generated from operations | -€18.1M | -€20.1M |
| Net cash from operating activities | -€18.3M | -€20.1M |
| Income taxes paid | €154.0K | €24.0K |
| Net cash from investing activities | €233.0K | -€684.0K |
| Purchase of PP&E (capex) | €341.0K | €707.0K |
| Purchase of intangibles | €114.0K | €0 |
| Net cash from financing activities | €5.5M | -€1.2M |
| Repayments of borrowings | €1.3M | €1.2M |
| Balance sheet | ||
| Total assets | €36.6M | €49.5M |
| Non-current assets | €11.7M | €11.8M |
| Property, plant & equipment | €4.9M | €5.3M |
| Right-of-use assets | €3.6M | €3.7M |
| Current assets | €24.9M | €37.8M |
| Trade & other receivables | €750.0K | €820.0K |
| Cash & equivalents | €21.6M | €34.1M |
| Total equity | €25.6M | €38.1M |
| — attributable to owners | €25.6M | €38.1M |
| Non-current liabilities | €5.5M | €5.4M |
| Long-term borrowings | €4.8M | €5.3M |
| Current liabilities | €5.5M | €6.0M |
| Trade & other payables | €2.6M | €4.2M |
| Derived metrics | ||
| Free cash flow | -€18.6M | -€20.8M |
| Return on equity | -80.2% | -59.6% |
| Cash conversion ratio | 0.89× | 0.88× |
| Capex coverage | -53.62× | -28.42× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Current Assets | €257.0K | -€467.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | €89.0K | -€247.0K |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €1.8M | €1.6M |
| Adjustments For Increase Decrease In Other Current Liabilities | €1.7M | -€304.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€1.6M | €997.0K |
| Adjustments For Provisions | -€27.0K | -€55.0K |
| Adjustments For Sharebased Payments | €1.0M | €1.7M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€18.5M | -€20.0M |
| Comprehensive Income Attributable To Owners of Parent | -€20.5M | -€22.8M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €1.2M | €1.2M |
| Deferred Tax Assets | €18.0K | €125.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €5.0K | €6.0K |
| Equity and Liabilities | €36.6M | €49.5M |
| Finance Income | €939.0K | €320.0K |
| General and Administrative Expense | €5.7M | €5.1M |
| Increase Decrease In Cash and Cash Equivalents | -€12.5M | -€22.0M |
| Increase Decrease Through Sharebased Payment Transactions | €1.0M | €1.7M |
| Increase Decrease Through Transfers and Other Changes Equity | €6.9M | €0 |
| Intangible Assets Other Than Goodwill | €642.0K | €596.0K |
| Interest Paid Classified As Financing Activities | €159.0K | €245.0K |
| Interest Received Classified As Investing Activities | €658.0K | €23.0K |
| Issue of Equity | €16.0K | €236.0K |
| Issued Capital | €46.2M | €44.5M |
| Liabilities | €11.0M | €11.4M |
| Miscellaneous Other Operating Income | €2.6M | €2.9M |
| Noncurrent Provisions | €91.0K | €89.0K |
| Noncurrent Provisions For Employee Benefits | €23.0K | €16.0K |
| Other Comprehensive Income | -€36.0K | -€39.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation Other Than Translation of Foreign Operations | -€7.0K | €4.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€29.0K | -€43.0K |
| Other Current Financial Assets | €2.1M | €2.1M |
| Other Current Nonfinancial Assets | €490.0K | €746.0K |
| Other Current Nonfinancial Liabilities | €1.7M | €592.0K |
| Other Inflows Outflows of Cash Classified As Operating Activities | €115.0K | €0 |
| Other Noncurrent Assets | €2.6M | €2.0M |
| Other Noncurrent Liabilities | €512.0K | €0 |
| Other Reserves | €4.1M | €3.1M |
| Proceeds From Issuing Other Equity Instruments | €7.0M | €236.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €29.0K | €0 |
| Research and Development Expense | €16.6M | €18.8M |
| Retained Earnings | -€40.2M | -€19.7M |
| Sales and Marketing Expense | €1.2M | €1.6M |
| Share Premium | €15.5M | €10.2M |
Every line item above is a fact tagged in Biotalys's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.